Imugene Enhances Portfolio with Compelling Oncolytic Virus from City of Hope, a Cancer Centre in Los Angeles, California
-
FDA Investigational New Drug (IND) package
-
Worldwide, exclusive licence with long patent life
-
Phase 1 clinical trial anticipated to commence in 2020
-
Ex-Viralytics members part of project team for development of the oncolytic virus
Sydney, 15 July 2019 – Australian immuno-oncology company Imugene Ltd (ASX:IMU), today announced that it would acquire Vaxinia Pty Ltd and separately acquire a worldwide exclusive license to a promising oncolytic virus technology, known as CF33, developed at City of Hope, a world-renowned independent research and treatment centre for cancer, diabetes and other life-threatening diseases based in Los Angeles, California.
For further information please download the attached PDF:
Download this document
